Safety Observer

Share on
LinkedIn
Twitter
Facebook
@email

Revised ABPI Guidance for PV in Market Research

ABPI has published a revised guidance on collecting Safety Information during Market Research Programmes (MRPs).

As reported to our clients in November 2018 (Report N°150), the ABPI (Association of the British Pharmaceutical Industry) has worked with BHBIA (British Healthcare Business Intelligence Association) to produce a revised version of their guidance on collecting Adverse Events, Product Complaints and Special Situations Reports during Market Research Programmes (MRPs). This is Version 4 of this valuable guidance document, which was first issued in October 2009.

ABPI issued an announcement (1) where the key changes are highlighted. In addition to changes related to Personal Data Protection, the main change concerns the collection of contact details when information is collected directly from patients/consumers in order to enable the appropriate follow-up of Adverse Events by the MAH.

For those who are not familiar with this document, it includes a series of useful annexes including example wording for the contract with the Market Research Agencies, templates for Data Collection and Reconciliation Forms, as well as interview scripts covering a range of scenarios.

The information presented on the BHBIA website (3) also includes the Microsoft Word templates for the Data Collection and Reconciliation Forms, as well as suggested wording for Market Research Materials and a series of “Quick Guides”.

Footnotes

(1) ABPI News Release: Link here

(2) BHBIA webpage – Adverse Event Reporting: Link here

Share on
LinkedIn
Twitter
Facebook
@email

Continue reading

Sign up for alerts

Receive alerts and news on pharmacovigilance regulatory requirements every month.

Register today!

Safety Observer

EUR (€)
My account

Social

3-Month Plan

This Plan includes three consecutive reports starting with the next release. The perfect solution to test the value of our service.

Starts at 180 

1-Year Plan

This Plan includes eleven consecutive reports starting with the next release. Includes a double issue for July/August.

Starts at 600 

Stay in the loop

Join over 1,000 Pharmacovigilance professionals and receive our Free Content straight to your mailbox !